AVIDITY BIOSCIENCES INC (RNA)
US05370A1088 - Common Stock
Taking everything into account, RNA scores 4 out of 10 in our fundamental rating. RNA was compared to 565 industry peers in the Biotechnology industry. While RNA has a great health rating, there are worries on its profitability. RNA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year RNA has reported negative net income.
RNA had a negative operating cash flow in the past year.
In the past 5 years RNA always reported negative net income.
RNA had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -17.09%, RNA belongs to the top of the industry, outperforming 81.28% of the companies in the same industry.
Looking at the Return On Equity, with a value of -18.66%, RNA belongs to the top of the industry, outperforming 86.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.09% | ||
| ROE | -18.66% | ||
| ROIC | N/A |
ROA(3y)-29.53%
ROA(5y)-25.48%
ROE(3y)-34.47%
ROE(5y)-30.71%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
RNA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RNA has more shares outstanding
RNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 22.54 indicates that RNA is not in any danger for bankruptcy at the moment.
RNA's Altman-Z score of 22.54 is amongst the best of the industry. RNA outperforms 94.12% of its industry peers.
There is no outstanding debt for RNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 22.54 |
ROIC/WACCN/A
WACC10.4%
2.3 Liquidity
RNA has a Current Ratio of 17.76. This indicates that RNA is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 17.76, RNA belongs to the best of the industry, outperforming 92.34% of the companies in the same industry.
A Quick Ratio of 17.76 indicates that RNA has no problem at all paying its short term obligations.
RNA has a better Quick ratio (17.76) than 92.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 17.76 | ||
| Quick Ratio | 17.76 |
3. Growth
3.1 Past
RNA shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.68%.
RNA shows a decrease in Revenue. In the last year, the revenue decreased by -0.23%.
The Revenue has been growing by 90.61% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)3.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.45%
Revenue 1Y (TTM)-0.23%
Revenue growth 3Y12.08%
Revenue growth 5Y90.61%
Sales Q2Q%-17.1%
3.2 Future
Based on estimates for the next years, RNA will show a very strong growth in Earnings Per Share. The EPS will grow by 26.87% on average per year.
RNA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 112.84% yearly.
EPS Next Y1.72%
EPS Next 2Y-3.78%
EPS Next 3Y-5.14%
EPS Next 5Y26.87%
Revenue Next Year-42.34%
Revenue Next 2Y-20.23%
Revenue Next 3Y50.28%
Revenue Next 5Y112.84%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RNA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RNA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as RNA's earnings are expected to decrease with -5.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.78%
EPS Next 3Y-5.14%
5. Dividend
5.1 Amount
RNA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AVIDITY BIOSCIENCES INC
NASDAQ:RNA (11/21/2024, 3:58:07 PM)
42.655
-0.99 (-2.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.09B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.09% | ||
| ROE | -18.66% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 17.76 | ||
| Quick Ratio | 17.76 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)3.68%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y1.72%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-0.23%
Revenue growth 3Y12.08%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y